{"id":5966,"date":"2025-03-05T09:47:00","date_gmt":"2025-03-05T15:47:00","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5966"},"modified":"2025-07-13T15:10:40","modified_gmt":"2025-07-13T20:10:40","slug":"hc-wainwright-bioconnect-2025","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la 3.\u00aa edici\u00f3n anual de BioConnect Showcase de HC Wainwright"},"content":{"rendered":"
\n
\n
\n
\n
\n

\u00a0<\/p>\n<\/div>\n

\n
\n

DALLAS<\/span><\/span>,\u00a013 de marzo de 2025<\/span><\/span> \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida a restaurar la visi\u00f3n en personas ciegas o que la han perdido debido a diversas enfermedades degenerativas de la retina, anunci\u00f3 hoy que\u00a0Sulagna Bhattacharya<\/span>, director ejecutivo y cofundador de Nanoscope Therapeutics, se presentar\u00e1 en el HC Wainwright 3tercero<\/sup>\u00a0Presentaci\u00f3n anual de BioConnect, que se lleva a cabo\u00a016-18 de marzo de 2025<\/span>, en\u00a0Isla Kiawah, Carolina del Sur<\/span>. Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

La Sra. Bhattacharya ofrecer\u00e1 una descripci\u00f3n general de Nanoscope y brindar\u00e1 una actualizaci\u00f3n sobre las actividades cl\u00ednicas y corporativas de la Compa\u00f1\u00eda.\u00a0Lunes 17 de marzo<\/span>, en\u00a09:40 a. m., hora del este<\/span>\u00a0en el sal\u00f3n de baile Grand Oaks.<\/p>\n

El equipo ejecutivo estar\u00e1 disponible para reunirse con inversores durante el evento.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que actualmente no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer semestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>Tambi\u00e9n en el primer semestre de 2025, MCO-010 ha recibido las designaciones de v\u00eda r\u00e1pida de la FDA y de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un activo MCO-020 de administraci\u00f3n l\u00e1ser no viral, listo para IND, para AG, as\u00ed como un activo AAV para la amaurosis cong\u00e9nita de Leber, en estudios que facilitan IND.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u00a0 DALLAS,\u00a0March 13, 2025 \u2014\u00a0Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that\u00a0Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the H.C. Wainwright 3rd\u00a0Annual BioConnect Showcase, taking place\u00a0March 16-18, 2025, on\u00a0Kiawah Island, […]<\/p>\n","protected":false},"author":6,"featured_media":5975,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-05T15:47:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:10:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase\",\"datePublished\":\"2025-03-05T15:47:00+00:00\",\"dateModified\":\"2025-07-13T20:10:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/\"},\"wordCount\":270,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_Wainwright1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_Wainwright1.jpg\",\"datePublished\":\"2025-03-05T15:47:00+00:00\",\"dateModified\":\"2025-07-13T20:10:40+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_Wainwright1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_Wainwright1.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/hc-wainwright-bioconnect-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la tercera edici\u00f3n anual de BioConnect Showcase de HC Wainwright.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-03-05T15:47:00+00:00","article_modified_time":"2025-07-13T20:10:40+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase","datePublished":"2025-03-05T15:47:00+00:00","dateModified":"2025-07-13T20:10:40+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/"},"wordCount":270,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_Wainwright1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/","url":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la tercera edici\u00f3n anual de BioConnect Showcase de HC Wainwright.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_Wainwright1.jpg","datePublished":"2025-03-05T15:47:00+00:00","dateModified":"2025-07-13T20:10:40+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_Wainwright1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_Wainwright1.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/hc-wainwright-bioconnect-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5966"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5966\/revisions"}],"predecessor-version":[{"id":7226,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5966\/revisions\/7226"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5975"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}